Retinalgenix Technologies Inc. (RTGN) — SEC Filings
Retinalgenix Technologies Inc. (RTGN) — 12 SEC filings. Latest: 8-K (Mar 26, 2026). Includes 6 10-Q, 3 8-K, 2 10-K.
View Retinalgenix Technologies Inc. on SEC EDGAR
Overview
Retinalgenix Technologies Inc. (RTGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: RetinalGenix Technologies Inc. (RTGN) reported no revenue for the three and nine months ended September 30, 2025, continuing its pre-revenue stage. The company posted a net loss of $568,791 for the three months ended September 30, 2025, an improvement from a net loss of $644,291 in the same period o
Sentiment Summary
Across 12 filings, the sentiment breakdown is: 1 bearish, 11 neutral. The dominant filing sentiment for Retinalgenix Technologies Inc. is neutral.
Filing Type Overview
Retinalgenix Technologies Inc. (RTGN) has filed 3 8-K, 6 10-Q, 1 10-Q/A, 2 10-K with the SEC between Apr 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (12)
| Date | Form | Description | Risk |
|---|---|---|---|
| Mar 26, 2026 | 8-K | 8-K Filing | |
| Nov 14, 2025 | 10-Q | RetinalGenix Cash Dries Up Amid Mounting Losses, Going Concern Risk | high |
| Aug 20, 2025 | 10-Q/A | RetinalGenix Amends Q2 2025 10-Q Filing | medium |
| Aug 19, 2025 | 10-Q | RetinalGenix Technologies Inc. Files Q2 2025 10-Q | low |
| May 15, 2025 | 10-Q | RetinalGenix Technologies Inc. Files Q1 2025 10-Q | low |
| Mar 31, 2025 | 10-K | RetinalGenix Technologies Inc. Files 2024 Annual Report | medium |
| Feb 20, 2025 | 8-K | RetinalGenix Technologies Inc. Files 8-K | low |
| Nov 18, 2024 | 10-Q | RetinalGenix Technologies Inc. Files Q3 2024 10-Q | low |
| Aug 19, 2024 | 10-Q | RetinalGenix Technologies Inc. Files Q2 2024 10-Q | low |
| May 20, 2024 | 10-Q | RetinalGenix Technologies Inc. Files Q1 2024 10-Q | low |
| Apr 8, 2024 | 8-K | RetinalGenix Technologies Inc. to Acquire Private Company | medium |
| Apr 1, 2024 | 10-K | RetinalGenix Technologies Inc. Files 2023 Annual Report (10-K) | medium |
Risk Profile
Risk Assessment: Of RTGN's 11 recent filings, 1 were flagged as high-risk, 4 as medium-risk, and 6 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $(1,805,468) |
| EPS | $(0.10) |
| Debt-to-Equity | N/A |
| Cash Position | $92 |
| Operating Margin | N/A |
| Total Assets | $7,001 |
| Total Debt | $2,179,731 |
Key Executives
- Jerry Katzman
Industry Context
RetinalGenix Technologies Inc. operates in the biotechnology and medical device sector, focusing on ophthalmic and systemic diseases. This industry is characterized by long development cycles, high research and development costs, and stringent regulatory hurdles. Key areas of focus include diagnostics and therapeutics for conditions like diabetic retinopathy and Alzheimer's disease. The competitive landscape includes established pharmaceutical companies and numerous emerging biotech firms, all vying for funding and market share.
Top Tags
10-Q (6) · financials (4) · medical-devices (4) · quarterly-report (3) · quarterly-filing (2) · 10-K (2) · Biotechnology (1) · Ophthalmology (1) · Going Concern (1) · Liquidity Risk (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | for three and nine months ended September 30, 2025 and 2024, indicating pre-revenue stage |
| Net Loss (3 months) | $(568,791) | for three months ended September 30, 2025, an improvement from $(644,291) in 2024 |
| Net Loss (9 months) | $(1,805,468) | for nine months ended September 30, 2025, significantly lower than $(3,453,800) in 2024 |
| Cash | $92 | at September 30, 2025, a drastic decrease from $6,060 at December 31, 2024 |
| Total Liabilities | $2,179,731 | at September 30, 2025, an increase from $1,477,556 at December 31, 2024 |
| Accumulated Deficit | $17,235,490 | at September 30, 2025, indicating significant historical losses |
| Due to Sanovas | $539,052 | at September 30, 2025, highlighting reliance on related party financing |
| Stock-based compensation (9 months) | $759,348 | for nine months ended September 30, 2025, a decrease from $2,240,099 in 2024 |
| Common Shares Outstanding | 18,604,961 | at November 14, 2025, an increase from 18,522,295 at December 31, 2024 |
| Proceeds from stock sales | $186,000 | from selling 82,666 shares of common stock in 2025 |
| Reporting Period | Q2 2025 | The amended filing covers the second quarter of 2025. |
| Period End Date | 20250630 | The financial information pertains to the period ending June 30, 2025. |
| Filing Date | 20250820 | The amended 10-Q was officially filed on August 20, 2025. |
| Fiscal Year End | 1231 | Indicates the end of the company's annual accounting cycle. |
| SEC File Number | 333-258528 | Unique identifier for the company's SEC filings. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Retinalgenix Technologies Inc. (RTGN)?
Retinalgenix Technologies Inc. has 12 recent SEC filings from Apr 2024 to Mar 2026, including 6 10-Q, 3 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RTGN filings?
Across 12 filings, the sentiment breakdown is: 1 bearish, 11 neutral. The dominant sentiment is neutral.
Where can I find Retinalgenix Technologies Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Retinalgenix Technologies Inc. (RTGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Retinalgenix Technologies Inc.?
Key financial highlights from Retinalgenix Technologies Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RTGN?
The investment thesis for RTGN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Retinalgenix Technologies Inc.?
Key executives identified across Retinalgenix Technologies Inc.'s filings include Jerry Katzman.
What are the main risk factors for Retinalgenix Technologies Inc. stock?
Of RTGN's 11 assessed filings, 1 were flagged high-risk, 4 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Retinalgenix Technologies Inc.?
Forward guidance and predictions for Retinalgenix Technologies Inc. are extracted from SEC filings as they are enriched.